SUBSCRIBE
SUBSCRIBE
News   Business

Genelabs Technologies, Inc. Provides Update on Hepatitis C Drug Development with Collaboration Partners

June 23, 2008 | 
1 min read
REDWOOD CITY, Calif.--(BUSINESS WIRE)--Genelabs Technologies, Inc. (Nasdaq:GNLB) announced today that based on progress to date, its hepatitis C drug development and commercialization collaboration with Novartis is continuing to the next phase.
Alliances
Novartis
MORE ON THIS TOPIC
Illustration of cardboard box filled with office supplies, a computer keyboard, lamp, and a potted plant
Layoff Tracker
GSK restructure will hit home, impacting ‘limited’ UK roles
October 28, 2026
 · 
110 min read
 · 
BioSpace Editorial Staff
Balance vaccination and anti-vaccination. Vaccination or Anti-vaccination concept, vector illustration
Earnings
GSK vaccine sales miss expectations amid falling demand from adults
October 28, 2026
 · 
2 min read
 · 
Nick Paul Taylor
Hand shake icon on wooden cube block which connection with human icon for business deal and agreement concept.
Immuno-oncology
Astellas bets up to $1.34B for option to advance Audax immuno-oncology asset
October 28, 2026
 · 
2 min read
 · 
Tristan Manalac
Business growth or increase in professional income, business operations, investment profits or interest on savings, increase in interest rates, businessman holding gold coins forming a growing arrow symbol.
Earnings
Biogen notches 3rd straight quarter of growth thanks to newer products, Apellis
October 28, 2026
 · 
1 min read
 · 
Annalee Armstrong